Navigation Links
Neupro(R) Filed with the FDA for the Treatment of Restless Legs Syndrome
Date:12/13/2007

The U.S. Food and Drug Administration (FDA) has accepted for filing the

Supplemental New Drug Application (sNDA) for the use of Neupro(R) (Rotigotine Transdermal System) as a treatment for moderate-to-severe

restless legs syndrome (RLS)

ATLANTA, Dec. 13 /PRNewswire/ -- UCB announced today that the supplemental New Drug Application (sNDA) for the use of Neupro(R) as a treatment for moderate-to-severe restless legs syndrome (RLS) has been accepted for filing by the U.S. Food and Drug Administration (FDA). Neupro(R) is a patch designed to provide continuous drug delivery. Restless legs syndrome is a chronic neurological disorder that affects between three and ten percent of the population.

"The acceptance of the sNDA underscores our ongoing commitment to provide innovative therapies for patients living with debilitating central nervous system disorders," said Troy Cox, President CNS Operations, UCB.

The submission is based on two fixed-dose, randomized, double-blind, placebo-controlled efficacy and safety studies that evaluated rotigotine for the treatment of moderate-to-severe idiopathic RLS in approximately 1,000 patients over six months. In these trials, rotigotine produced statistically significant reductions in RLS symptoms and was generally well-tolerated. The efficacy of rotigotine was evaluated by monitoring the International Restless Legs Severity Scale (IRLS), a clinician-administered tool considered to be the best scale for evaluating the severity and frequency of RLS symptoms and the degree to which they affect sleep and daily life. The most frequently reported adverse events associated with rotigotine in these studies were application site reactions, nausea, dizziness, somnolence and headache.

"This chronic condition can be serious and even debilitating with many patients requiring treatment that offers sustained symptom control," said rotigotine study investigator Arthur S. Walters, MD, Professor, Department of Neuroscience, Seton Hall University School of Graduate Medical Education, and Director of the Center for Sleep Disorders Treatment, Research and Education at the New Jersey Neuroscience Institute at JFK Medical Center. "These study results showed that rotigotine significantly improved symptoms of restless legs syndrome throughout the six month trial period."

In July 2007 Neupro(R) was launched in the United States for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease. In Europe, Neupro(R) is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease as monotherapy and as adjunctive therapy with levodopa in advanced-stage Parkinson's disease.

About Restless Legs Syndrome:

Restless legs syndrome (RLS) is a chronic neurological disorder that affects between three and ten percent of the population. It is characterized by unpleasant feelings in the legs and an irresistible urge to move in order to relieve the discomfort. RLS sensations are frequently described as tingling, burning, tugging, gnawing and pulling. The exact cause of RLS is not known; however, recent clinical research has linked certain genes to RLS, suggesting that the disorder is biologically based.

Symptoms of RLS typically appear during periods of rest and inactivity, particularly in the evenings and at night. This can make it difficult to fall asleep and stay asleep, thus preventing recuperative sleep and often leading to daytime fatigue and reduced alertness. While RLS symptoms are generally most pronounced in the evening and while at rest, other periods of inactivity, such as long flights, car trips and sitting in a movie theater, can also trigger symptoms.

About Neupro(R) in the USA:

In the USA, Neupro(R) is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease as monotherapy. Neupro(R) delivers the dopamine agonist, rotigotine, directly from a patch into the bloodstream, through the skin and offers stable, continuous delivery of rotigotine 24 hours-a-day. Rotigotine is a drug that mimics dopamine, a chemical messenger that transmits impulses between nerve cells in the brain to produce smooth, coordinated movement. Neupro(R) offers once-daily dosing and a good tolerability profile.

Important Safety Information

Some patients treated with Neupro(R) reported falling asleep while engaged in activities of daily living, including operation of motor vehicles, which sometimes resulted in accidents. Some patients perceived no warning signs, such as excessive drowsiness. Hallucinations were reported in 2.0% of patients treated with Neupro(R) compared to 0.7% of patients on placebo. Neupro(R) should be used with caution in patients with cardiovascular disease because of the potential for symptomatic hypotension, syncope, elevated heart rate, elevated blood pressure, fluid retention, and/or weight gain. All Parkinson's disease patients are at a higher risk for melanoma and should be monitored regularly. The most commonly reported side effects (greater than or equal to 5%) in clinical trials were nausea, application site reactions, somnolence, dizziness, headache, vomiting, and insomnia. Some subjects who received Neupro(R) experienced a decline in blood hemoglobin levels (about 2% relative to subjects who received placebo). It is not known whether this change is readily reversible with discontinuation of Neupro(R). For full prescribing information, please visit http://www.neupro.com.

About UCB

UCB, Brussels, Belgium (http://www.ucb-group.com) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing around 12,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB S.A. is listed on the Euronext Brussels Exchange and, through its affiliate, owns approx. 89% of the shares of SCHWARZ PHARMA AG. SCHWARZPHARMA (Monheim, Germany) is a member of the UCB Group.

Forward looking statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.


'/>"/>
SOURCE UCB
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Neupro(R) Filed with the FDA for the Treatment of Advanced-Stage Parkinsons Disease
2. Claim Filed Against the Company and Nine Other Defendants in the Haifa Magistrates Court
3. First Nationwide Class Action Filed on Behalf of Consumers Who Purchased Topps E. Coli Contaminated Ground Beef
4. First Nationwide Class Action Filed Against ConAgra on Behalf of Consumers Who Purchased or Ingested Salmonella Contaminated Pot Pies
5. Federal Charges Filed Against Community Medical Centers Management
6. Amicus Brief Filed with U.S. Supreme Court in Riegel v. Medtronic, Inc.
7. Shareholder Class Action Filed Against Aetna Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
8. Another Medtronic Sprint Fidelis Lead Lawsuit is Filed in Federal District Court
9. Class Action Lawsuit Filed Against 15 California Nursing Homes
10. New treatment effective in counteracting cocaine-induced symptoms
11. New treatment boosts muscle function in myasthenia gravis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , ... December 07, 2016 , ... “Tomorrow Trump Goes ... Trump bringing greatness back to the presidency and to America. “Tomorrow Trump Goes To ... do as much as she can for this country. , Nancy attributes her patriotic ...
(Date:12/7/2016)... WI (PRWEB) , ... December 07, 2016 , ... ... Labs, was honored to present at the International Probiotic Association’s Washington DC workshop ... and government regulators to engage in dialog regarding probiotic dietary supplement regulations. ...
(Date:12/6/2016)... ... December 06, 2016 , ... Men ... a higher risk of serious health problems, such as cardiovascular illness, according to ... Soleymani of Beverly Hills Periodontics & Dental Implant Center notes that the correlation ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... health management, announces today a strategic relationship with CitiusTech, a leading healthcare ... engine that offers advanced Clinical Quality Measures (CQM) computation capabilities (as a ...
(Date:12/6/2016)... ... December 06, 2016 , ... CarriersEdge, providers of online ... new suite of Driver Wellness courses. Offered in three modules, the courses can be ... so fleets can educate drivers about how to stay healthy on the road. , ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... NEW YORK , Dec. 6, 2016 ... atomic nucleus. Radioisotopes are produced either by using nuclear ... energy in the form of alpha, beta or gamma ... thus emitted are used in Nuclear medicine, specifically in ... to provide diagnostic information about a human body,s functioning. ...
(Date:12/6/2016)... 6, 2016 Human Vaccines Market: Scope ... wise and country wise analysis of the human ... of human vaccines products, raw material suppliers, vaccine ... the market. The report provides qualitative and ... Qualitative analysis comprises market dynamics, trends, product overview, ...
(Date:12/6/2016)... BOLTON, Miss. , Dec. 6, 2016 ... and rescue personnel in a simulated mass casualty event ... Mississippi . The technology debuted before an audience ... Bryant and representatives from Homeland Security, Federal Law ... Telemedical Drone Project, known as HiRO (Health Integrated Rescue ...
Breaking Medicine Technology: